NCT07480681 2026-03-18
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
Shanghai Henlius Biotech
Phase 1 Not yet recruiting